A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis

CyBorD: stellar response rates in AL amyloidosis

(2012) G. Merlini   BLOOD

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

(2012) J. R. Mikhael et al.   BLOOD

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

(2012) C. P. Venner et al.   BLOOD

Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

(2012) Shaji Kumar et al.   JOURNAL OF CLINICAL ONCOLOGY

Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis

(2011) J. E. Ward et al.   BLOOD

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

(2011) D. E. Reece et al.   BLOOD

High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement

(2011) S. Madan et al.   BLOOD

Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis

(2011) S O Schönland et al.   BONE MARROW TRANSPLANTATION

Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis

(2011) A. D. Wechalekar et al.   HAEMATOLOGICA

Amyloidosis: Pathogenesis and New Therapeutic Options

(2011) Giampaolo Merlini et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay

(2010) A. V. Kristen et al.   BLOOD

The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis

(2010) G. Palladini et al.   BLOOD

Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement

(2010) S. Dietrich et al.   BLOOD

Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis

(2010) Efstathios Kastritis et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

(2010) Karl Bodin et al.   NATURE

Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

(2008) Giovanni Palladini et al.   ANNALS OF HEMATOLOGY